Medpage Today on MSN2d
Which High-Risk Patients Should Get the RSV Vaccine?
The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
MyChesCo on MSN5mon
FDA Approves New RSV Vaccine for Individuals Aged 50-59
and chronic obstructive pulmonary disease (COPD). These conditions can compromise the immune system, making it harder to ...
The American Journal of Managed Care22d
GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults
Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data.
McKnight's Long-Term Care News1mon
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
Additional data from the phase 3 trial showed the vaccine came with a 94.1% effectiveness in preventing severe RSV when people got it during the first season and 64.2% a year later, the company ...
infectiousdiseaseadvisor.com9d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
MyChesCo on MSN1mon
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...
Business Wire21d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine ... as chronic obstructive pulmonary disease (COPD ...
Medscape1mon
Pulmonary Medicine News
GSK RSV Shot 43% Effective Against Severe Disease in Third Year GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was ... to Worse Outcomes in Pulmonary Embolism Location ...
WebMD3y
Adult Vaccines Resource Center
An all-encompassing guide to understanding vaccines. CDC Recommends People Ages 50 to 64 Get Pneumococcal VaccinesThe CDC now says everyone 50 to 64 years old should get a pneumococcal vaccine to ...
Yahoo Finance15d
GSK sales hampered by slump in demand for key vaccine
Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...
Yahoo Finance15d
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...
Science Daily3d
Vaccines News
Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...